Marketing

GSK hopes $3-bil. off-label settlement will end legal woes

Marc Iskowitz November 07, 2011

GlaxoSmithKline's deal to resolve multiple US investigations into its sales and marketing practices—one of the largest settlements by a pharma company—aims to patch up several long-running legal disputes.

Pfizer's post-expiry plan for Lipitor: maximize brand's sales

Marc Iskowitz November 02, 2011

Pfizer said it plans not only to keep Lipitor consumer promotions running past the brand's expiry later this month. It also aims to put an OTC version of the megablockbuster on the market at some point.

Feds subpoena Merck on marketing of hepatitis, cancer drugs

Marc Iskowitz August 08, 2011

Merck said it received a subpoena related to marketing and selling activities with respect to three drugs: Temodar, PegIntron and Intron A.

Pain drug monitoring firm enticed docs to use test, qui-tam suit charges

Marc Iskowitz July 06, 2011

A national lab promised doctors they could enrich themselves by as much as $2 million a year through a scheme that involved billing payers multiple times for the same urinary drug test, a whistleblower suit alleges.

Off-label marketing offenses cost Elan $203 million

Marc Iskowitz March 01, 2011

Elan Pharmaceuticals pleaded guilty today to a misdemeanor violation for illegally promoting epilepsy drug Zonegran.

In Coumadin banter, lessons for marketers of new blood thinners

Marc Iskowitz October 27, 2010

A love-hate relationship for Coumadin (warfarin) is playing out online, say authors of a new report that may offer lessons for marketers of new blood-thinning products.

Novartis held the line on sales and marketing spend in 2009

Matthew Arnold January 26, 2010

Novartis' US sales reorg seems to have paid off in 2009 as the company held the line on sales and marketing expenses despite a passel of global launches.

Ax falls at Merck as CEO talks sales cuts

Marc Iskowitz January 07, 2010

Eight weeks after the completion of Merck's merger with Schering-Plough, the new company is making staff cuts while hinting of more in commercial and manufacturing areas.

Abbott's next step for Niaspan

Marc Iskowitz January 05, 2010

Abbott Labs' cholesterol drug Niaspan is growing prescription share nicely after a clinical trial highlighted its potential as part of a one-two punch in reducing plaque. Now, the company says, it is considering how best to capitalize on the data.

Zogenix and Astellas to co-promote migraine injectable

Ben Comer August 03, 2009

California-based Zogenix announced a partnership with Astellas to co-promote Sumavel DosePro, a subcutaneous injection for migraine relief.

Making Marketing Dollars Count: Made to Measure

Deborah Dick-Rath July 15, 2009

In an age of accountability, where every dollar counts, Deborah Dick-Rath talks to industry insiders about how they can make a measurable difference in their marketing mix